Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

Canaan Registers Upbeat Q1; Aims To Navigate Through Bitcoin Price Fluctuation

Canaan Inc (NASDAQ:CAN) reported first-quarter FY22 revenue growth of 236.7% year-on-year to $213.9 million. Earnings per ADS were $0.41. The Y/Y increase was mainly attributable to the rise in total computing power sold and the average selling price per Thash/s. Total computing power sold increased 119.1% Y/Y to 4.3 million Thash/s. Canaan held…

Benzinga

Read Why Did Tricida Stop VALOR-CKD Renal Outcomes Trial Early

Tricida Inc (NASDAQ:TCDA) said that, as anticipated, it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons under the existing study protocol to allow for six months of financial runway following topline results, currently anticipated in early Q4 2022. VALOR-CKD trial, initiated in 2018, was designed to evaluate veverimer's ability to…

Benzinga

This Sugarbeet Cooperative Looks To Overcome Truck Driver Shortage - Read How Kratos Helps

Kratos Defense & Security Solutions, Inc (NASDAQ:KTOS) has teamed with the Minn-Dak Farmers Cooperative (MDFC) to launch self-driving trucks, easing the truck driver shortage burden using Kratos Autonomous Systems. MDFC is a farmer-owned sugarbeet cooperative headquartered in Wahpeton, North Dakota. The collaboration combines Kratos' unmanned system technologies with Minn-Dak's agriculture and transportation expertise.…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Mid-Morning Market Update: Markets Open Lower; US Jobless Claims Increase To 218,000

U.S. stocks traded lower this morning, with the Dow Jones dipping more than 300 points on Thursday.

Benzinga

Why NeuroMetrix Shares Are Skyrocketing

NeuroMetrix Inc (NASDAQ: NURO) shares are trading higher by 30.10% at $4.06 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.

Benzinga

Palo Alto Networks Whale Trades For May 19

Someone with a lot of money to spend has taken a bearish stance on Palo Alto Networks (NASDAQ:PANW). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Universal Debuts Trailer For 'Bros,' First Gay Rom-Com From A Hollywood Studio

Comcast Corp.’s (NASDAQ: CMCSA) Universal Pictures has released a trailer for “Bros,” the first gay romantic comedy that is going into a nationwide theatrical release by a major Hollywood studio.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

FTX US Launches Stock Trading: What Traders And Investors Need To Know

Cryptocurrency exchange FTX is making the leap into U.S. equity trading.

Benzinga

Why Bitcoin-Related Stock Canaan Is Skyrocketing

Shares of cryptocurrency-related company Canaan Inc - ADR (NASDAQ: CAN) are trading higher by 16.24% at $3.65 after the company reported first-quarter earnings results.

Benzinga

5 Analysts Have This to Say About Sumo Logic

Sumo Logic (NASDAQ:SUMO) has observed the following analyst ratings within the last quarter:

Benzinga

Expert Ratings for Sarepta Therapeutics

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2022

Upgrades

Benzinga

5 Analysts Have This to Say About GDS Holdings

GDS Holdings (NASDAQ:GDS) has observed the following analyst ratings within the last quarter:

Benzinga

Analog Devices's Return on Invested Capital Overview

According to Benzinga Pro, during Q2, Analog Devices (NASDAQ:ADI) earned $783.27 million, a 179.66% increase from the preceding quarter. Analog Devices also posted a total of $2.97 billion in sales, a 10.73% increase since Q1.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Horizon Therapeutics Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Horizon Therapeutics (NASDAQ:HZNP) earned $204.26 million, a 17.95% increase from the preceding quarter. Horizon Therapeutics's sales decreased to $885.25 million, a 12.7% change since Q4.

Benzinga

Seres Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter.

Benzinga

Editas Medicine's Return On Capital Employed Insights

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter.

Benzinga

Gentherm Earnings Perspective: Return On Invested Capital

According to Benzinga Pro data Gentherm (NASDAQ:THRM) posted a 41.41% decrease in earnings from Q4. Sales, however, increased by 7.83% over the previous quarter to $267.66 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Wingstop's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Wingstop (NASDAQ:WING) earned $8.68 million, a 25.81% increase from the preceding quarter. Wingstop also posted a total of $76.20 million in sales, a 5.8% increase since Q4.

Benzinga

Gibraltar Industries Earnings Perspective: Return On Capital Employed

According to Benzinga Pro, during Q1, Gibraltar Industries (NASDAQ:ROCK) earned $15.46 million, a 65.09% increase from the preceding quarter. Gibraltar Industries's sales decreased to $317.87 million, a 4.96% change since Q4.

Benzinga

As Nvidia Stock Slides, Here's How To Play The Counter-Trend

NVIDIA Corporation (NASDAQ: NVDA) plunged over 6% during Wednesday’s trading session in sympathy with the S&P 500, which shed 4%.

Benzinga

Expert Ratings for Argo Blockchain

Within the last quarter, Argo Blockchain (NASDAQ:ARBK) has observed the following analyst ratings:

Benzinga

Replimune Group: Q4 Earnings Insights

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Replimune Group missed estimated earnings by 3.45%, reporting an EPS of $-0.6 versus an estimate of $-0.58.

Benzinga

Expert Ratings for Aptinyx

Within the last quarter, Aptinyx (NASDAQ:APTX) has observed the following analyst ratings:

Benzinga

Executives Buy Around $17M Of 5 Penny Stocks

The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their…

1 … 437 438 439 440

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.